Looking ahead, there are several areas of possible focus for the next update of DrugBank. As previously mentioned, we continue to develop ML-powered tools to process and structure publicly available data at scale and deliver targeted details to curators for manual approval. Combined with potential improvements to the detail captured for each drug–target interaction, this could represent an invaluable resource to those working in the drug development space. Other areas for continued advancement include those that are more focused on DrugBank's architecture and user interfaces. Although we have made great strides in terms of tracking data lineage, there is still more development needed to enable a truly robust tracking system. Similarly, new ML-powered tools to automatically track and report issues within our systems would be welcome additions to avoid interruptions in uptime, erroneous alterations of data and other such concerns.
